GASTROENTEROLOGY PRESCRIPTION FORM

Faxed prescriptions will only be accepted from a prescribing practitioner. Patients must bring an original prescription to the pharmacy. Prescribers are reminded patients may choose any pharmacy of their choice.

Owl Specialty Pharmacy

1010 E. Arrow Hwy., Covina, CA 91724 Phone: 626-209-8169 Fax: 626-209-8171 or 855-817-9523





	Patien	t Information: please	e provide a cop	y of the pa	tient's insu	rance card or inf	ormation			
Patient Name:			DOB:		Gender: □ F □ M H		HT:		WT:	
Address:			City:		State:	Zip Code:	<u>'</u>	Phone:		
Insurance: Subscriber's name:					ID#:			Group #:		
Allergies: ☐ NKDA ☐ List alle	rgies:	•						•		
Clinical D	Diagnosis: please t	fax or email relevant o	clinical notes, la	ıbs, tests aı	nd previou	ıs medical history	to expedite p	rior authoriz	ration	
Diagnosis / ICD-10:			· · ·		•	•	<u> </u>			
TB Test/Date:			Prior Therapies:							
□ Patient is currently on therap	y (Start date/_	/)		1						
		Hepatic En	cephalopathy	/ IBS-D / 1	raveler's	Diarrhea				
Medication	Strength	Directions					Quantity	Refills		
□ Xifaxan®	□ 200 mg		☐ Take one 200 mg tablet by mouth three times a day for 3 days							
	□ 550 mg		\Box Take one 550 mg tablet by mouth two times a day							
		☐ Take one 550 mg tablet by mouth three times a day for 14 days								
		Cı	rohn's Disease	e / Ulcerati	ve Colitis					
Medication	Strength	Directions					Quantity	Refills		
☐ Diflicid	☐ 200 mg tablet					0 days with or witho				
☐ Humira® Citrate Free	☐ Starter Kit - 80mg / 0.8mL		☐ Inject 160 mg SC day 1; 80 mg day 15; two weeks later (Day 29), begin a maintenance dose of 40 mg every other week							
	\square 40 mg/ 0.4 mL pens or prefilled syringes		☐ Inject 40 mg SC every other week							
☐ Entyvio®	ntyvio® □ 300 mg/ 20 mL vial			☐ Infuse IV 300 mg weeks 0, 2, 6						
			☐ Infuse IV 300 mg every 8 weeks							
☐ Relistor®	□ 8 mg syringe (Pt's weight 38-61kg)		☐ Inject 1 syringe SC Once Daily							
	☐ 12 mg syringe (Pt's weight 62-114kg) ☐ Othermg		☐ Inject 1 syringe SC Once Daily ☐ Injectmg SC Once Daily							
	☐ 150 mg tablets		☐ Take 3 Tablets (450 mg total) by mouth once daily in the morning							
☐ Remicade®	☐ 100 mg/ 20 mL vial		☐ Infuse IV 5 mg/ kg weeks 0, 2, 6							
		☐ Infuse IV 5 mg/ kg every 8 weeks								
			□ Infuse IV							
☐ Rinvoq®	☐ 45 mg ER Tab		45 mg PO qd x 8 weeks							
	☐ 30 mg ER Tab ☐ 15 mg ER Tab		□ 30 mg PO qd□ 15 mg PO qd							
☐ Simponi®	☐ 100 mg/ mL Smartject® Autojector		☐ Inject SC 200 mg week 0; 100 mg weeks 2, 6							
_ c poe	□ 100 mg/ mL PFS		☐ Inject SC 100 mg every 4 weeks							
☐ Skyrizi®	☐ 600 mg Infusion		☐ Infuse IV 600 mg on weeks 0, 4, 8							
	☐ 360 mg Auto- Inj	☐ 360 mg Auto- Inject device		☐ 360 mg SC every 8 weeks. Start 4 weeks after last induction dose.						
☐ Stelara®	□ 90 mg/ mL PFS		□ Inject SC 90 mg dose 8 weeks after the initial IV dose, then every 8 weeks Date of initial IV dose:mg IV for one dose.							
	☐ 130 mg/ 26 ml Infusion		Date of linital iv dose Indiseing iv for one dose.							
□ Xeljanz®	☐ 10 mg tablet		☐ Take 10 mg PO twice daily ☐ Other							
	☐ XR 22 mg tablet	☐ XR 22 mg tablet		☐ Take 22 mg PO once daily						
☐ Zinplava®	☐ 10 mg/kg IV		☐ Infuse 10 mg	/kg IV over 60) minutes as	s a single dose				
□ Other:										
			Prescribe	r Informati	on					
Prescriber name:					Phone:		Office contact name:			
Prescriber address:				City:	<u>[</u>			State:	Zip:	
NPI: DEA:				Fax and/or Email:				<u> </u>		
Proposibor cigrof			I □ DO NOT 1				SUBSTITUTE			
Prescriber signature:					Date:			ו או אים וי	oudo IIIU IE	

Important Notice: This facsimile transmission is intended to be delivered only to the named recipient(s), and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named recipient, immediately notify the sender at the address and phone number set forth herein and obtain instructions as to properly dispose of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except authority of the sender to the named addressee.